OFFICIAL PUBLICATION OF

by its subsidiary APPco

TGA issues inhaler alert

Nicholas O’Donoghue 31/01/2024

No recall for Boehringer Ingelheim’s Spiriva Respimat Solution for Inhalation 2.5μg, despite issues with the product's inhaler device Patients are being urged to continue using Boehringer Ingelheim’s Spiriva Respimat Solution for Inhalation 2.5μg, despite an alert from the Therapeutic Goods Administration (TGA) regarding the product’s inhaler device. The TGA said that the alert

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Teal questions pharmacist UTI programs

because much of the time, I think they’re giving antibiotics for things that are not UTIsPolitician says "I think" and…

Michael Hewson

Medics to ‘fight’ Doctor of Pharmacy title

Yet right now there are far too many reports from overseas of patients being unsure whether their care is from…

Michael Hewson

In scarce supply

I love a good joke.

Evan Nickols

Concurrent funding for aged care pharmacists and RMMRs needed

I understood that was to happen as a gradual changeover and not an abrupt cessation. Currently we do not have…

Jenny Gowan

TGA issues inhaler alert

Previous Silos, restrictions and inconsistency named as scope barriers

Next ‘Every time there is a disaster…’

Ceramides: what are they and why are they important?

In the beginning

The signs of ageing

Hyperpigmentation

MENU

Previous Silos, restrictions and inconsistency named as scope barriers

Next ‘Every time there is a disaster…’

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.